In this trial of 156 patients on low-dose ASA (80mg) who developed peptic-ulcer-related GI bleeding, they were randomized, after endoscopic control of the bleeding, to continue ASA or placebo. Recurrent GI bleeding at 30-days was significantly higher in the ASA group (10% vs 5%), but the ASA group had lower 8-week all-cause mortality (1% vs 13%). Although ASA cessation after peptic-ulcer bleeding is associated with lower 30-day bleeding risk, it is also associated with higher 8-week mortality (abstract). It may be beneficial to immediately re-start the ASA in some patients.
Share This Post
Categories
Related Posts
Do you have a stack of journals piling up on your desk, beside your bed or in your email inbox? In 1950, medical knowledge was estimated to double every 50 years, but now the doubling time is every few months. At this rate, it is impossible to keep up with the literature, but a group […]
This large systematic review found rectal NSAIDs significantly reduced the risk of post-ERCP pancreatitis compared to pancreatic duct stents (abstract).
This large population-based cohort found the most common causes of drug induced liver injury to be augmentin and diclofenac, followed by herbal and nutritional supplements (abstract).
Leave A Comment